Cytotoxic Drug Antibodies

Creative Diagnostics offers monoclonal and polyclonal antibodies against different categories of cytotoxic drug: Tubulin Inhibitor; DNA Damaging; RNA Polymerase II and III Inhibitor; DNA Topoisomerase I Inhibitor and DNA Inhibitor.

Currently, the launched products are for research purposes only, not for use in diagnostics. More payload antibodies are under development.

ADCs (Antibody–drug conjugates) are emerging as powerful cancer treatments that combine antibody-mediated tumor targeting with the potent cytotoxic activity of toxins and permit sensitive discrimination between healthy and diseased tissue. Due to its high potent toxins, the pharmacokinetic properties need to be extensively evaluated. So, the ratio of conjugated and total antibody needs to be measured using immuno-colorimetric assays by an agent that targets the drug portion after certain time period of deployment.

With team of antibody experts working in a state-of-the-art laboratory, Creative Diagnostics is proud to announce that a new set of antibodies specific to Cytotoxic Drugs are now commercially available. Using these newly launched antibodies, we were able to successfully develop highly sensitive MMAE and MMAF ELISA kits.

More in development, coming soon!